Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varithena for Venous Leg Ulcer Healing
NCT02988063Phase 4Withdrawn
- Sponsor
- OhioHealth
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polidocanol in venous leg ulcer (VLU), sponsored by OhioHealth. Primary endpoint: Ulcer healing rate at 12 weeks. Planned start Apr 2017; status: withdrawn.
02
Drugs
polidocanol
03
Conditions
venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT02988063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988063.